21186 ⎘
Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
Sub-classes:GLYCOTARGETING THERAPEUTICS
#2SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES
#3SARS-CoV-2 Vaccine Constructs
#4Process for Producing of Vaccine Formulations With Preservatives
#5GLYCOTARGETING THERAPEUTICS
#6LIVE ATTENUATED ZIKA VIRUS WITH 3'UTR DELETION, VACCINE CONTAINING AND USE THEREOF
#7MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME
#8Cattle fever tick-infestation vaccines and uses thereof
#9Foot-and-mouth disease vaccine
#10PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE
#11SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES
#12CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOF
#13SYSTEMS AND METHODS TO IMPROVE VACCINE EFFICACY
#14METHODS OF TREATING SOLID TUMORS USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY
#15GLYCOTARGETING THERAPEUTICS
#16Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#17COMPOSITIONS AND METHODS FOR ENHANCING INNATE IMMUNITY IN A SUBJECT FOR TREATMENT OF INFECTIONS AND CANCER AND OTHER ACUTE AND CHRONIC CONDITIONS OF THE EYE
#18Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
#19African swine fever (ASF) virus vaccines
#20Peptide vaccine formulations and use thereof for inducing an immune response
#21Foot-and-mouth disease vaccine
#22Pan-antiallergy vaccine
#23PREDICTIVE BIOMARKERS FOR AN IMMUNE RESPONSE
#24COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES
#25TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS
#26TARGET PEPTIDES FOR COLORECTAL CANCER THERAPY AND DIAGNOSTICS
#27Compositions for stabilizing and delivering proteins
#28Composition comprising poly I:C and LAG-3-IGG fusion protein
#29Compositions and uses
#30Immunogenic RSV polypeptides
#31Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
#32Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#33Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof
#34SIMULTANEOUS IN VITRO ANALYSIS OF VACCINE POTENCY AND TOXIN CONCENTRATION
#35Glycotargeting therapeutics
#36Systems and methods to improve vaccine efficacy
#37Glycotargeting therapeutics
#38Foot-and-mouth disease vaccine
#39Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
#40Vaccine nanotechnology
#41Vaccine
#42Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
#43Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
#44TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS
#45HEV vaccine
#46Therapeutic compositions and methods with cytokine signaling immunomodulators
#47Peptide vaccine formulations and use thereof for inducing an immune response
#48Mesenchymal stem cells as vaccine adjuvants and methods for using the same
#49Skin microenvironment targeted delivery for promoting immune and other responses
#50Method of reducing reactogenicity induced by administration of vaccine or immunogenic composition
#51Foot-and-mouth disease vaccine
#52VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES
#53Bird flu vaccine combination comprising virus-like particles and novel adjuvants
#54Pneumococcal capsular saccharide conjugate vaccine
#55Method for inducing early T memory response with short peptides anti-tumor vaccine
#56Immunogenic RSV polypeptides
#57Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#58ISG15 and its use as an adjuvant
#59Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
#60DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS
#61Compositions and uses
#62Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
#63Compositions and methods for enhanced innate immunity
#64Glycan conjugates and use thereof
#65Compositions for stabilizing and delivering proteins
#66Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
#67Immunostimulator and method for producing the same
#68Method for producing outer membrane vesicles
#69Method for treating amyloid disease
#70Glycotargeting therapeutics
#71Vaccine comprising capsular polysaccharide conjugates
#72Process for stabilizing an adjuvant containing vaccine composition
#73Swine dysentery vaccine
#74Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
#75Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
#76Glycotargeting therapeutics
#77Dose selection of adjuvanted synthetic nanocarriers
#78Target peptides for colorectal cancer therapy and diagnostics
#79Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
#80Pneumoccal polysacchride conjugate vaccine
#81Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
#82Method for treating amyloid disease
#83Methods and compositions for inhibiting diseases of the central nervous system
#84Method for immunizing an avian species
#85Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
#86Vaccine nanotechnology
#87Process for stabilizing an adjuvant containing vaccine composition
#88Vaccine nanotechnology
#89Vaccine nanotechnology
#90Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
#91Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease
#92VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
#93Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
#94Method for treating amyloid disease
#95Human prostate cell lines in cancer treatment
#96VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
#97Cancer therapy
#98Anti-RSV immunogens and methods of immunization
#99Vaccine
#100RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF
#101Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
#102Porcine circovirus type 2B isolate and uses thereof
#103Dose selection of adjuvanted synthetic nanocarriers
#104Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof
#105SYNTHETIC NANOCARRIER COMBINATION VACCINES
#106MULTIVALENT SYNTHETIC NANOCARRIER VACCINES
#107NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT
#108FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS
#109T-cell immunogens derived from anti-viral proteins and methods of using same
#110Chimeric HIV Antigens
#111RABIES VACCINE
#112METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE
#113SYSTEM AND PROCESS FOR PRODUCING MULTI-COMPONENT BIOPHARMACEUTICALS
#114Protein vaccines against poxviruses
#115Vaccine for treatment and prevention of herpes simplex virus infection
#116METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
#117Activation of natural killer (NK) cells and methods of use
#118Device including bone cage and method for treatment of disease in a subject
#119Device including bone cage and method for treatment of disease in a subject
#120Dendritic cell vaccine compositions and uses of same
#121Vaccine nanotechnology
#122Protein vaccines against poxviruses
#123METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES
#124THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE
#125Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
#126TRANSDERMAL IMMUNE PREPARATION, METHOD FOR PRODUCTION OF THE SAME, AND TRANSDERMAL IMMUNIZATION METHOD USING THE SAME
#127Materials and methods for immunizing against FIV infection
#128Pneumococcal polysaccharide conjugate vaccine
#129Pharmaceutical Compositions Containing Monoclonal Anti-Idiotypic Anti-Ca-125 Antibody and Aluminium Derivatives
#130Novel Compositions and Uses Thereof
#131MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED ADJUVANT
#132Soluble Fragments of The Sars-Cov Spike Glycoprotein
#133Vaccines for mycoplasma bovis and methods of use
#134Method for immunizing an avian species
#135Process for stabilizing an adjuvant containing vaccine composition
#136Vaccines for Mycoplasma bovis and methods of use
#137Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
#138Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
#139Heteroclitic analogs and related methods
#140DNA EXPRESSION VECTORS
#141Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium
#142Human prostate cell lines in cancer treatment
#143Vaccine
#144Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates
#145Pneumococcal Polysaccharide Conjugate Vaccine
#146Vaccines for Mycoplasma bovis and methods of use
#147Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
#148Compositions and methods for enhancing an adjuvant
#149Vaccine Composition Against Hepatitis C Virus
#150Vaccines for and methods of use
#151Immunogenic Hiv Compositions and Related Methods
#152Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
#153Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#154Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
#155Methods and compositions for treatment of cancer
#156Composition and method for the treatment of carcinoma
#157DERP1 AND PRODERP1 ALLERGEN DERIVATIVES
#158Equine protozoal myeloencephalitis vaccine
#159Vaccines for mycoplasma bovis and methods of use
#160Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#161Stabilized immunogenic HBc chimer particles
#162Epstein-barr-virus-specific immunization
#163Soluble fragments of the SARS-CoV spike glycoprotein
#164Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
#165Materials and methods for immunizing against FIV infection
#166Compositions with enhanced immunogenicity
#167Vaccine composition comprising methylated DNA and immunomodulatory motifs
#168Activation of natural killer (NK) cells and methods of use
#169Antigens for raising an immune response against rickettsieae and ehrlichieae pathogens
#170Recombinant lentivirus encoding modified GP 120 signal sequences
#171Methods and products for enhancing epitope spreading
#172Immunogenic HIV compositions and related methods
#173Vaccines for and methods of use
#174Human prostate cell lines in cancer treatment
#175Vaccines for and methods of use
#176Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
#177Materials and methods for immunizing against FIV infection
#178Human prostate cell lines in cancer treatment